uploads/2018/05/Praluent.png

How Regeneron’s Praluent and Dupixent Performed in 1Q18

By

Updated

Praluent revenue trends

In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17, which reflected a ~67% rise on a YoY (year-over-year) basis and a ~5% rise quarter-over-quarter.

In March, Regeneron Pharmaceuticals and Sanofi (SNY) publicized the success of the ODYSSEY OUTCOMES trial. In the ODYSSEY OUTCOMES trial, high-risk patients on Praluent and maximally-tolerated statins demonstrated a significant reduction in major adverse cardiovascular events compared to patients receiving only statins.

Article continues below advertisement

In May, Regeneron and Sanofi announced that they’d decided to lower the net price of the Praluent injection for more affordable access of the drug to patients from Express Scripts. With this decision, Praluent will be the exclusive PCSK9 inhibitor in the Express Script national formulary. The agreement is expected to substantially simplify the documentation required for securing insurance coverage for eligible patients and lead to a decrease in out-of-pocket expenses.

The steps the companies have taken to ensure easy access to Praluent are expected to boost the drug’s revenue growth. In the marketplace, Praluent’s peers include Amgen’s (AMGN) Repatha.

Dupixent revenue trends

In 1Q18, Dupixent generated revenue of $131 million compared to $139 million and $88.9 million in 3Q17 and 4Q17, respectively.

Presently, Regeneron is conducting clinical studies to evaluate the safety and efficacy of Dupixent (dupilumab) for the treatment of adolescent and pediatric atopic dermatitis, eosinophilic esophagitis, and nasal polyps. Regeneron expects the data from its Phase 3 clinical trials with Dupixent for the treatment of adolescents with atopic dermatitis and nasal polyps to be read out during 2018.

In April, the European Medicines Agency accepted for review Regeneron Pharmaceuticals and Sanofi’s application for Dupixent as an additional maintenance therapy for the treatment of adolescents and adults with not properly controlled moderate to severe asthma.

The application for regulatory approval has been supported by data from the LIBERTY ASTHMA clinical trial. In the atopic dermatitis drugs market, some common drugs include Valeant Pharmaceuticals’ (VRX) Elidel, Pfizer’s (PFE) Eucrisa, and Bayer’s (BAYZF) Desonate.

Advertisement

More From Market Realist